Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 75, Issue 1, 2010, Pages 33-41

  Yang, Wei ^a   Johnston, Keith P ^b   Williams, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

Aerosol; In vivo; Inhalation; Lung; Nebulization; Pharmacokinetics; Poorly water soluble drug; Supersaturation

Indexed keywords

ITRACONAZOLE; NANOCRYSTAL; NANOMATERIAL; NANOPARTICLE;

AEROSOL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; COLLOID; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG SOLUBILITY; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; ITRACONAZOLE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77951652999     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.01.011     Document Type: Article

References (59)

1. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods 2000, 44(1):235-249.
2. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997, 23(1-3):3-25.
3. Muller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Advanced Drug Delivery Reviews 2001, 47(1):3-19.
4. Patravale V.B., Date A.A., Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. Journal of Pharmacy and Pharmacology 2004, 56(7):827-840.
5. Agharkar S., Lindenbaum S., Higuchi T. Enhancement of solubility of drug salts by hydrophilic counterions - properties of organic salts of an antimalarial drug. Journal of pharmaceutical sciences 1976, 65(5):747-749.
6. Amin K., Dannenfelser R.M., Zielinski J., Wang B. Lyophilization of polyethylene glycol mixtures. Journal of pharmaceutical sciences 2004, 93(9):2244-2249.
7. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical Research 2007, 24(1):1-16.
8. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. Journal of Pharmaceutical Sciences 1996, 85(11):1142-1169.
9. Liu R. Water-insoluble Drug Formulation 2000, CO Interpharm Press, Englewood.
10. Grant D.J.W., Brittian H.G. Physical Characterisation of Pharmaceutical Solids 1995, Marcel Dekker, New York.
11. Hintz R.J., Johnson K.C. The effect of particle-size distribution on dissolution rate and oral absorption. International Journal of Pharmaceutics 1989, 51(1):9-17.
12. Borm P., Klaessig F.C., Landry T.D., Moudgil B., Pauluhn J., Thomas K., Trottier R., Wood S. Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicological Sciences 2006, 90(1):23-32.
13. Blagden N., de Matas M., Gavan P.T., York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Advanced Drug Delivery Reviews 2007, 59(7):617-630.
14. Liversidge G.G., Cundy K.C. Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs. 1. Absolute Oral bioavailability of nanocrystalline danazol in beagle dogs. International Journal of Pharmaceutics 1995, 125(1):91-97.
15. Mauludin R., Muller R.H., Keck C.M. Development of an oral rutin nanocrystal formulation. International Journal of Pharmaceutics 2009, 370(1-2):202-209.
16. Chiang P.C., Alsup J.W., Lai Y.R., Hu Y.D., Heyde B.R., Tung D. Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Research Letters 2009, 4(3):254-261.
17. Kraft W.K., Steiger B., Beussink D., Quiring J.N., Fitzgerald N., Greenberg H.E., Waldman S.A. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. Journal of Clinical Pharmacology 2004, 44(1):67-72.
18. Kassem M.A., Rahman A.A.A., Ghorab M.M., Ahmed M.B., Khalil R.M. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. International Journal of Pharmaceutics 2007, 340(1-2):126-133.
19. Pignatello R., Bucolo C., Ferrara P., Maltese A., Puleo A., Puglisi G. Eudragit RS100 (R) nanosuspensions for the ophthalmic controlled delivery of ibuprofen. European Journal of Pharmaceutical Sciences 2002, 16(1-2):53-61.
20. Ganta S., Paxton J.W., Baguley B.C., Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. International Journal of Pharmaceutics 2009, 367(1-2):179-186.
21. Kipp J.E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. International Journal of Pharmaceutics 2004, 284(1-2):109-122.
22. Courrier H.M., Butz N., Vandamme T.F. Pulmonary drug delivery systems: recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier Systems 2002, 19(4-5):425-498.
23. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharmaceutical Research 2000, 17(4):397-404.
24. Hancock B.C., Zograf G. Characteristics and significance of the amorphous state in pharmaceutical systems. Journal of pharmaceutical sciences 1997, 86(1):1-12.
25. Hilden L.R., Morris K.R. Physics of amorphous solids. Journal of Pharmaceutical Sciences 2004, 93(1):3-12.
26. Betageri G.V., Makarla K.R. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. International Journal of Pharmaceutics 1995, 126(1-2):155-160.
27. Matteucci M.E., Miller M.A., Williams R.O., Johnston K.P. Highly supersaturated solutions of amorphous drugs approaching predictions from configurational thermodynamic properties. Journal of Physical Chemistry B 2008, 112(51):16675-16681.
28. Gupta P., Chawla G., Bansal A.K. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility. Molecular Pharmaceutics 2004, 1(6):406-413.
29. Matteucci M.E., Brettmann B.K., Rogers T.L., Elder E.J., Williams R.O., Johnston K.P. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Molecular Pharmaceutics 2007, 4(5):782-793.
30. Tam J.M., McConville J.T., Williams R.O., Johnston K.P. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. Journal of Pharmaceutical Sciences 2008, 10.1002/jps.21367.
31. Yang W., Tam J., Miller D.A., Zhou J., McConville J.T., Johnston K.P., Williams R.O. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. International Journal of Pharmaceutics 2008, 361(1-2):177-188.
32. Vaughn J.M., McConville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., Williams R.O. Single dose and multiple dose studies of itraconazole nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2006, 63(2):95-102.
33. McConville J.T., Overhoff K.A., Sinswat P., Vaughn J.M., Frei B.L., Burgess D.S., Talbert R.L., Peters J.I., Johnston K.P., Williams R.O. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharmaceutical Research 2006, 23(5):901-911.
34. Hoeben B.J., Burgess D.S., McConville J.T., Najvar L.K., Talbert R.L., Peters J.I., Wiederhold N.P., Frei B.L., Graybill J.R., Bocanegra R., Overhoff K.A., Sinswat P., Johnston K.P., Williams R.O. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 2006, 50(4):1552-1554.
35. Peeters J., Neeskens P., Tollenaere J.P., Van Remoortere P., Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 2002, 91(6):1414-1422.
36. Overhoff K.A., Engstrom J.D., Chen B., Scherzer B.D., Milner T.E., Johnston K.P., Williams R.O. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics 2007, 65(1):57-67.
37. Cook R.O., Pannu R.K., Kellaway I.W. Novel sustained release microspheres for pulmonary drug delivery. Journal of Controlled Release 2005, 104(1):79-90.
38. Wiedmann T.S., DeCastro L., Wood R.W. Nebulization of nanocrystals(TM): production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharmaceutical Research 1997, 14(1):112-116.
39. Deng Z., Xu S., Li S. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. International Journal of Pharmaceutics 2008, 351(1-2):236-243.
40. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharmaceutical Research 2007, 24(3):411-437.
41. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics 2000, 50(1):47-60.
42. Crisp M.T., Tucker C.J., Rogers T.L., Williams R.O., Johnston K.P. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. Journal of Controlled Release 2007, 117(3):351-359.
43. Tinke A.P., Vanhoutte K., De Maesschalck R., Verheyen S., De Winter H. A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution. Journal of Pharmaceutical and Biomedical Analysis 2005, 39(5):900-907.
44. Courrier H.M., Butz N., Vandamme T.F. Pulmonary drug delivery systems: recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier Systems 2002, 19(4-5):425-498.
45. Altiere R., Thompson D. Inhalation Aerosols-Physical and Biological Basis for Therapy 1996, 85-138. Marcel Dekker, Inc., New York. A. Hickey (Ed.).
46. Martonen T.B., Katz I.M. Deposition patterns of aerosolized drugs within human lungs - effects of ventilatory parameters. Pharmaceutical Research 1993, 10(6):871-878.
47. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release 2003, 86(1):131-144.
48. B.Y. Shekunov, P. Chattopadhyay, D. Yim, D. Cippola, B. Boyd, Formulation and in vitro performance of drug-lipid nanosuspensions for pulmonary delivery, in: Conference on Respiratory Drug Delivery, Boca Raton, Florida, 2006, pp. 609-612.
49. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nature Reviews 2007, 6(1):67-74.
50. Aguiar A.J., Zelmer J.E. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. Journal of Pharmaceutical Sciences 1969, 58(8):983-987.
51. Aguiar A.J., Krc J., Kinkel A.W., Samyn J.C. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. Journal of Pharmaceutical Sciences 1967, 56(7):847-853.
52. Miller D.A., McConville J.T., Yang W., Williams R.O., McGinity J.W. Hot-melt extrusion for enhanced delivery of drug particles. Journal of Pharmaceutical Sciences 2007, 96(2):361-376.
53. Sanna V., Gavini E., Cossu M., Rassu G., Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. Journal of Pharmacy and Pharmacology 2007, 59(8):1057-1064.
54. Sinswat P., Overhoff K.A., McConville J.T., Johnston K.P., Williams R.O. Nebulization of nanoparticulate amorphous or crystalline tacrolimus - single-dose pharmacokinetics study in mice. European Journal of Pharmaceutics and Biopharmaceutics 2008, 69(3):1057-1066.
55. Yang W., Peters J.I., Williams R.O. Inhaled nanoparticles - a current review. International Journal of Pharmaceutics 2008, 356(1-2):239-247.
56. Matteucci M.E., Paguio J.C., Miller M.A., Williams R.O., Johnston K.P. Highly supersaturated solutions from dissolution of amorphous itraconazole microparticles at pH 6.8. Molecular Pharmaceutics 2009, 6(2):375-385.
57. Nemmar A., Vanbilloen H., Hoylaerts M.F., Hoet P.H., Verbruggen A., Nemery B. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. American Journal of Respiratory and Critical Care Medicine 2001, 164(9):1665-1668.
58. Forsgren P., Modig J., Gerdin B., Axelsson B., Dahlback M. Intrapulmonary deposition of aerosolized evans blue-dye and liposomes in an experimental porcine model of early Ards. Upsala Journal of Medical Sciences 1990, 95(2):117-136.
59. Zhou H.Y., Zhang Y.L., Biggs D.L., Manning M.C., Randolph T.W., Christians U., Hybertson B.M., Hg K.Y. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. Journal of Controlled Release 2005, 107(2):288-299.